Systemic anticancer therapy administration safety
نویسندگان
چکیده
منابع مشابه
PP2A-Mediated Anticancer Therapy
PP2A is a family of mammalian serine/threonine phosphatases that is involved in the control of many cellular functions including protein synthesis, cellular signaling, cell cycle determination, apoptosis, metabolism, and stress responses through the negative regulation of signaling pathways initiated by protein kinases. Rapid progress is being made in the understanding of PP2A complex and its f...
متن کاملOcular toxicity of systemic anticancer chemotherapy
The increased use of chemotherapeutic agents has resulted in longer cancer patient survival. Consequently the ophthalmologist is seeing more patients with adverse ocular side effects secondary to these antineoplastic agents. Ocular toxicity induced by cancer chemotherapy includes a broad spectrum of disorders, reflecting the unique anatomical, physiological and biochemical features of the eye. ...
متن کاملManagement of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines.
Most anticancer treatments carry a risk for infusion reactions (IRs); incidence may increase when different agents are administered concomitantly. IRs are either allergic reactions to foreign proteins [generally immunoglobulin E (IgE)-mediated allergic responses] or non-immune-mediated reactions [1]. Most IRs are mild with symptoms such as chills, fever, nausea, headache, skin rash, pruritus, e...
متن کاملDo medical oncologists and cancer patients care about treatment costs of systemic anticancer therapy?
PURPOSE The incidence, and thus the economic burden of cancer are increasing rapidly with prolongation of lifespan thanks to newly-developed anticancer drugs. Globally the number of newly diagnosed cases is expected to rise to 21.4 million by the year 2030. In this survey, our purpose was to investigate the level of awareness of oncologists and cancer patients concerning the treatment costs of ...
متن کاملSystemic anticancer therapy (SACT) for lung cancer and its potential for interactions with other medicines
BACKGROUND Systemic anticancer therapy, comprising chemotherapy agents alongside targeted therapies and immunotherapy, is clinically indicated for late-stage lung cancer. It is delivered in regimens often containing multiple anticancer agents as well as supportive care medicines to reduce side effects, raising potential for polypharmacy and therefore the possibility of drug-drug interactions wi...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Oncology
سال: 2018
ISSN: 0923-7534
DOI: 10.1093/annonc/mdy276.011